Sub $2.00 stock;
Our strategy is to build value for patients and shareholders by:
•
Completing the pivotal Phase 3 randomized, multicenter PRESENT ( P revention of R ecurrence in E arly- S tage, N ode-Positive Breast Cancer with Low-to-Intermediate HER2 E xpression with N euVax T reatment) study of our lead product candidate, NeuVax™ (nelipepimut-S) in 700 patients under a U.S. Food and Drug Administration (FDA)-approved Special Protocol Assessment (SPA); Vacine to prevent cancer. When is the test completed? What if 1 person has a recurrence?
•
Supporting our investigators with completion of the Phase 2b randomized, multicenter, investigator-sponsored clinical trial in 300 HER2 1+ and 2+ breast cancer patients to study NeuVax in combination with Herceptin® (trastuzumab; Genentech/Roche);P2 many years from commercial use
•
Supporting our investigators with initiation and completion of the Phase 2 randomized, multicenter, investigator-sponsored trial to study NeuVax in combination with Herceptin in high-risk HER2 3+ breast cancer patients who have received neoadjuvant therapy;P2 many years from commercial use
•
Supporting our partner, Dr. Reddy’s Laboratories' initiation and completion of the Phase 2 gastric cancer trial with NeuVax in India;P2 many years from commercial use
•
Completing the Phase 2 clinical trial of GALE-301 (folate binding protein (FBP)) cancer immunotherapy in ovarian and endometrial cancer;
•P2 many years from commercial use
Completing a Phase 2 clinical trial with GALE-401 (anagrelide controlled release (CR)) in patients with myeloproliferative neoplasms, including essential thrombocythemia (ET);P2 many years from commercial use
•
Achieving revenue goals for Abstral ® (fentanyl) sublingual tablets, for which we acquired the U.S. rights in March 2013 and launched in the fourth quarter of 2013;Finally revenue, but I have not seen a projection
•
Launching Zuplenz ® (ondansetron) Oral Soluble Film in the U.S. during the first quarter of 2015;See above and
•
Pursuing strategic alliances and acquisitions of other therapeutic products to complement our existing product pipeline and commercialization capabilities.
I don't see any reason for investing now. But I keep it on my watchlist and look for a new entry point.
